Related Experiment Videos
Summary
Verapamil taken twice daily (bd) effectively manages stable angina pectoris, showing similar efficacy to four times daily (qd) dosing. This dosing schedule improves exercise capacity and angina thresholds without increasing adverse effects.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Stable angina pectoris is a common cardiovascular condition.
- Optimizing medication regimens is crucial for effective angina management and patient adherence.
Purpose of the Study:
- To compare the efficacy and safety of verapamil administered twice daily (bd) versus four times daily (qd) in patients with stable angina pectoris.
- To evaluate the impact of different verapamil dosing frequencies on subjective angina symptoms and objective exercise test parameters.
Main Methods:
- A placebo-controlled, double-blind, crossover trial involving 12 patients with stable angina.
- Patients received verapamil (160 mg bd or 80 mg qd) or placebo for three-week periods.
- Assessments included subjective patient reports and treadmill exercise testing.
Main Results:
- Both verapamil regimens (bd and qd) significantly reduced angina symptoms and delayed ST segment depression during exercise compared to placebo.
- No significant differences in efficacy were observed between the twice-daily and four-times-daily verapamil regimens.
- Patients on verapamil twice daily demonstrated similar improvements in exercise capacity and angina threshold as those on four-times-daily dosing, with no increase in adverse effects.
Conclusions:
- Verapamil administered twice daily is an effective treatment option for patients with stable angina pectoris.
- Twice-daily verapamil offers comparable efficacy to four-times-daily dosing, providing a potentially more convenient regimen without compromising safety or effectiveness.